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Abstract
Background: The Natural History and Neuroprotection in Parkinson Plus Syndromes (NNIPPS) study was a large phase III
randomized placebo-controlled trial of riluzole in Progressive Supranuclear Palsy (PSP, n=362) and Multiple System Atrophy
(MSA, n=398). To assess disease severity and progression, we constructed and validated a new clinical rating scale as an
ancillary study.
Methods and Findings: Patients were assessed at entry and 6-montly for up to 3 years. Evaluation of the scale’s
psychometric properties included reliability (n=116), validity (n=760), and responsiveness (n=642). Among the 85 items of
the initial scale, factor analysis revealed 83 items contributing to 15 clinically relevant dimensions, including Activity of daily
Living/Mobility, Axial bradykinesia, Limb bradykinesia, Rigidity, Oculomotor, Cerebellar, Bulbar/Pseudo-bulbar, Mental,
Orthostatic, Urinary, Limb dystonia, Axial dystonia, Pyramidal, Myoclonus and Tremor. All but the Pyramidal dimension
demonstrated good internal consistency (Cronbach a$0.70). Inter-rater reliability was high for the total score (Intra-class
coefficient=0.94) and 9 dimensions (Intra-class coefficient=0.80–0.93), and moderate (Intra-class coefficient=0.54–0.77) for
6. Correlations of the total score with other clinical measures of severity were good (rho$0.70). The total score was
significantly and linearly related to survival (p,0.0001). Responsiveness expressed as the Standardized Response Mean was
high for the total score slope of change (SRM=1.10), though higher in PSP (SRM=1.25) than in MSA (SRM=1.0), indicating a
more rapid progression of PSP. The slope of change was constant with increasing disease severity demonstrating good
linearity of the scale throughout disease stages. Although MSA and PSP differed quantitatively on the total score at entry
and on rate of progression, the relative contribution of clinical dimensions to overall severity and progression was similar.
Conclusions: The NNIPPS-PPS has suitable validity, is reliable and sensitive, and therefore is appropriate for use in clinical
studies with PSP or MSA.
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Introduction
Progressive Supranuclear Palsy (PSP) and Multiple System
Atrophy (MSA), sometimes termed ‘parkinson plus’ syndromes,
account for 10–20% of parkinsonian syndromes [1–3], although
these figures may be an overestimate being derived from autopsy
studies. Both diseases are associated with severe disability and
early death [4–7]. PSP and MSA most commonly present with an
akinetic-rigid syndrome, with additional features such as
dysautonomia and cerebellar features in MSA, or oculomotor,
bulbar, cognitive and behavioral abnormalities in PSP [2], [8].
However, the expression of these features is variable during the
evolution of these syndromes, and although some are regarded as
typical of PSP (e.g., supranuclear ophthalmoplegia, dementia) or
of MSA (e.g., dysautonomia, cerebellar syndrome), there is
considerable overlap between the two disorders [8–12]. In
addition, if we are to study these disorders early in their
evolution, then a generic ‘parkinson plus’ scale is required, and
such a scale should capture all important aspects of the severity of
the clinical syndromes. To date, no scale designed to assess
severity and disease progression over the many functional
dimensions relevant to parkinson plus syndromes has been
developed and fully validated. Although the Unified Parkinson’s
Disability Rating Scale (UPDRS) [13] has been used in PSP [11],
[14] and MSA [15], [16], assessment of its metric qualities has
not been completed in this population. While the PSP Rating
Scale (PSP-RS) [5],[17] and the Unified Multiple System
Atrophy Rating Scale (UMSARS) [18–20] were designed
specifically for PSP and MSA respectively, neither of these scales
was designed to cover the full spectrum of disability in atypical
parkinsonian (‘parkinson plus’) syndromes or to capture func-
tional deficits in early MSA or PSP when the diagnosis remains
uncertain. Indeed, a scale that can with equal validity be applied
to either disease in the early stages is as important in the
investigation of natural history as it is in clinical trials. As part of
the NNIPPS study [8] we therefore developed a clinical scale
applicable in large multicentre trials that would allow evaluation
of atypical parkinsonian syndromes at all stages, while also
providing useful measures of change across the whole course of
disease evolution.
Thus our main objectives were to evaluate disease severity and
progression in PSP and MSA in relation to treatment; to
ascertain that prognostic factors at entry were balanced between
treatment groups; and to provide candidate covariates for survival
analysis. Critically, the NNIPPS study was designed with
stratification according to diagnosis at entry (PSP versus MSA)
and required balanced numbers of patients in each stratum. This
allows independent assessments of the results for each condition,
and unbiased comparisons of symptom severity between diseases.
Here we present the symptom severity profile and rate of
progression in each disorder as evaluated with the NNIPPS-PPS
scale, along with its psychometric properties, including face and
content validity, construct validity, inter-rater reliability, and
responsiveness.
Materials and Methods
Ethics approval
The protocol and amendments were reviewed and approved by
the Comite ´ de Protection des Personnes of Pitie ´-Salpe ˆtrie `re
Hospital (France), the UK Multicentre Research Ethics Commit-
tee (MREC), (UK), Ethikkommission of the University of Ulm,
(Germany), and by local Institutional Review Boards (Ethics
Committees) where appropriate (UK, Germany).
Trial design
The NNIPPS study was granted approval by the relevant
Institutional review boards and all subjects gave fully informed
signed consent before enrolment. Patients with an akinetic-rigid
syndrome diagnosed as PSP or MSA according to the NNIPPS
diagnostic criteria [8] were eligible. Details of the therapeutic trial
design and results have been reported previously [8]. In brief, the
intent to treat population comprised 760 patients (362 PSP and
398 MSA) recruited in 44 centers in the UK, France and
Germany. Patients were stratified according to diagnosis and
randomized double-blind to riluzole or placebo. The study was
powered to demonstrate efficacy within each strata independently.
The primary efficacy measure was survival, and secondary
endpoints were rates of change in functional scores. Patients were
evaluated 6-monthly for 3 years until death or the administrative
cut-off date.
Scale construction
Prior to the start of the trial, items were selected through
expert consensus as part of a broad clinical description of both
MSA and PSP. The dimensions included (i) functional disability
(activities of daily living), (ii) mental function (cognition, mood &
behavior); (iii) extra-pyramidal motor disability (rigidity, brady-
k i n e s i a ) ,( i v )t r e m o r ,( v )o c u l o m o t o r function, (vi) cerebellar signs,
(vii) pyramidal signs, (viii) dysautonomia, (ix) bulbar/pseudobul-
bar symptoms, (x) myoclonus, and (xi) dystonia. Items were
selected from the following scales available at that time, the
UPDRS (all items from Mental, ADL and Motor examination
sections) [13], the PSP-RS (six items from the mental section)
[17], three items from the International Cooperative Ataxia
Rating Scale (ICARS) [21], the global ataxia score of the
Expanded Disability Status Scale (EDSS ) [22], and four items
evaluating orthostatic signs and three for urinary signs from the
Autonomic Symptom Profile [23] adapted to interview record
instead of self-rating. Additional items were included to assess
oculomotor signs, dystonia, myoclonus, pyramidal signs, sitting down and
strength of cough.
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study to check each item and category wording. Redundant or
inappropriate items were eliminated to obtain the first version
comprising 85 items to be tested. Severity levels of items ranged
from 0 (‘‘normal’’) to a maximum of 6 (very severe), with a
majority of items (65) scored on a 5-point scale (0–4) (Supporting
information S1). Four sections were interview based with patient
and/or caregiver (Mental, Activities of Daily Living-ADL,
orthostatic and urinary signs), eleven were assessed through
examination. Time to complete the scale was 30–45 minutes
depending on clinical state of patient. Throughout the study, the
scale was completed in all centres using an English version.
Psychometric properties
According to the recommendations of the American Psycho-
logical Association [24], we evaluated face and content validity,
construct validity (Factor analysis, internal consistency, convergent
and predictive validity) [25] (Supporting information S2). Total
score and dimensional sub scores were obtained from summing
item scores overall or within dimensions, respectively.
For convergent validity we used Spearman rank correlations
with other clinical measures a priori considered as related to disease
severity. These included the Hoehn & Yahr staging (HYS) [26],
Schwab & England Activity daily Living scale (SEADL) [27], the
Mini Mental State Examination (MMSE) [28], the Frontal
Assessment Battery (FAB) [29], the Clinician Global Impression
of disease severity (CGI-ds) [25], 6 visual analog scales (VAS) of
syndromes severity (akinesia-rigidity, dysautonomia, cerebellar,
pyramidal, bulbar/pseudo-bulbar, behavioral and cognitive dys-
function), a CGI–dysautonomia score [8] and two quality of life
scales, the Parkinson’s disease questionnaire (PDQ-8) [30] and the
short form 36 health questionnaire (SF36) [31]. Correlations were
considered for rho$0.40. For predictive validity, relation between
scores at inclusion and survival was evaluated using univariate and
multivariate Cox model analysis [32].
Reliability
An inter-rater reliability study was conducted with sub-samples
of patients recruited from 11 centers (France: n=3, UK: n=3,
Germany: n=5). At inclusion, patients were evaluated twice
independently on the same day. To assess inter-rater agreement,
Cohen’s linear weighted kappa (kw) or simple kappa (k) for binary
items was calculated for each item [33], [34]. For the dimensional
sub scores and the total score, Fisher’s intra-class coefficients (ICC)
were computed using analysis of variance (ANOVA) with a one-
way random effect model [35]. Inter-rater reliability coefficients
were interpreted according to proposed standards for strength of
agreement as: #0.20=poor, 0.01–0.20=slight, 0.21–0.40=fair,
0.41 to 0.60=moderate, 0.61–0.80=substantial, and 0.81–
1.0=almost perfect [36]. Individual item strength of agreement
was considered as acceptable for k.0.40 (moderate to almost
perfect); for dimensional sub scores, ICC threshold for acceptabil-
ity was raised to 0.70. Internal consistency of the total and
dimensional scores was evaluated through Cronbach a coefficients
and considered acceptable for a.0.70.
Sensitivity to change
For each patient with at least two usable assessments, repeated
measurements of the NNIPPS-PPS total score and dimensional
sub scores were summarized by the slope of change (annual rate of
change in scores), using unweighted least-square regression
estimates [37]. To assess independence of change relative to
severity stage, we compared total score slope of change across the
whole range of severity grades defined by the CGI-ds (one-way
anova with test of trend). To test scale sensitivity to treatment
effects, mean slopes were compared between the treated and
placebo groups using two-way anova including treatment,
diagnostic strata, and treatment by strata interaction factors.
Responsiveness was further evaluated using effect size (ES)
defined as the ratio of the difference in slopes of change between
treatment groups to the Standard Deviation (SD) of placebo (mean
slope riluzole – mean slope placebo/SD slopes placebo). To assess
change within MSA and PSP strata and overall, we used the
standardized response mean (SRM) defined as the ratio of the
mean score change to the standard deviation (SD) of the score
change. The SRM and ES values were interpreted as small (0.20
to 0.49), moderate (0.50 to 0.79) or large (.0.80) [38].
For power calculations and assessment of scale efficiency,
sample size estimates were calculated within MSA and PSP strata
and overall (p (a)=0.05, p(12b)=0.80), using the total NNIPPS-
PPS score slopes expressed as annual rate of change, those of the
UPDRS motor score and SEADL, and those reported for
UMSARS [39] and PSP-RS [5].
To explore the dimensional profiles of PSP and MSA, means
and SD of scale scores at entry or of score slopes of change were
calculated for the overall population and broken down by
diagnostic strata (PSP versus MSA); Within diagnostic strata,
these were tested for significance with Student’s t test comparing
means to a theoretical value of 0, and across diagnostic strata, with
Student’s t test for independent groups. For graphical represen-
tation of severity profiles at entry and at follow-up, mean
dimensional scores at entry and mean slopes of change were
expressed as percent of maximum dimensional scores. To assess
the relative contribution of each dimension to overall severity
within each disease, mean dimensional scores (at entry) and
dimensional slopes of change were also expressed as percent of
total score and of total score slope of change, respectively.
All analyses were conducted on the Intent to Treat population
(ITT, or sub-groups of the ITT where appropriate), using SAS
(9.1.1) software. Significance level was set at p,0.05 (2-sided),
except when comparing dimensional sub scores between groups,
where Bonferroni correction for multiple comparisons was applied
(p,0.003).
Results
The characteristics of the trial population and main results are
reported in detail elsewhere [8]. The NNIPPS diagnostic criteria,
validated prospectively against pathology, proved highly sensitive
and specific, and the NNIPPS sample was broadly representative
of the PSP and MSA patient population. Patients alive at the end
of the study had at least 30 months follow-up and a total of 342
patients deceased during the trial (47% PSP patients, 43% MSA
patients). Disease severity was comparable in both treatment
groups at entry. On follow-up, since there was no treatment effect,
on any primary or secondary efficacy measures, data from placebo
and riluzole groups were combined.
Face and content validity
All items of the scale were clearly understood by trial
investigators, and considered appropriate to measure severity of
PSP and MSA syndromes. The expert neurologists advised that all
relevant dimensions for assessment of severity of both diseases
were reasonably well represented with the items selected.
Construct validity
Due to poor rate of completion, the item ‘‘erectile dysfunction’’
was excluded from the scale prior to analysis. For the Principal
Validation of the NNIPPS - PARKINSON PLUS SCALE
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missing (11% of cases) were excluded. The analysis population
included complete records of 675 patients (PSP n=317; MSA
n=358). The Principal Component Analysis (PCA) extracted 15
factors, altogether contributing to 62% of total variance (Table
S1), with clearly identifiable clinical meaning, and corresponding
to the a priori defined clinical dimensions. A single item, ‘‘sensory
complaints’’ not correlating with any factor was further excluded
from the scale. The first factor, consisting of two sets of items, 7
interview-based assessing activity of daily living and 7 from motor
examination, was split for further analyses into two clinical
dimensions ADL/Mobility and Axial Bradykinesia respectively. Items
assessing tremor, correlating with 2 separate factors (Tremor at rest
and Postural tremor), were combined into one single dimension
(Tremor) as rest tremor symptoms were either absent or mild in
these patients. The resulting 83-item scale, summarized into 15
dimensional sub scores and a total score, underwent thorough
validation and was used to evaluate disease severity and
progression. The internal consistency of the total score was
excellent (Cronbach a=0.92), and acceptable to high for all
dimensional sub scores (Cronbach a=0.68–0.94) except the
Pyramidal score (Cronbach a=0.39) (Table 1). Convergent validity
was good as shown by the high correlation of the total score with
global severity scales such as the CGI-ds (r=0.72), HYS (r=0.76)
and SEADL (r=20.80). Moderate correlation was found with
Quality of Life scales (with PDQ-8: r=0.48, SF-36 physical score
r=20.58). The ADL/mobility, Axial and Limb bradykinesia, and
Bulbar-pseudobulbar sub scores were the most correlated (r=0.49–
0.85) with HYS, SEADL, and the CGI-ds (Table S2). Correlations
of Cerebellar, Pyramidal, Rigidity, Bulbar/pseudo bulbar, Mental, Limb
Bradykinesia and Axial Bradykinesia, Orthostatic and Urinary sub-scores
with their corresponding VAS were satisfactory (r=0.52–0.76).
Correlations of the Orthostatic and Urinary scores with the CGI
dysautonomia were also satisfactory (respectively r=0.53 and
0.64). The Mental score correlated moderately with the FAB
(r=20.49) and the MMSE (r=20.46). No relationship (r,0.30)
with age or disease duration was found for any of the NNIPPS-
PPS scores. This weak correlation with the disease duration could
partly be explained by the bivariate distribution, with a substantial
proportion of patients with low CGI-ds (1–3) in those with longer
disease duration above 5 years (34%, i.e., slow progressors) and
high CGI-ds (4–6) in those with short disease duration (,3 years)
(37%, i.e., fast progressors). The convergent validity was further
supported by the good discrimination between the two extreme
groups of GCI-ds scores, with total score and 11 out 15
dimensional scores significantly higher (p,0.003 with Bonferroni
correction) in the high severity group (Figure 1).
The total score showed PSP patients to be slightly more severe
at entry than MSA patients (Table 1). As inevitable in view of our
strata inclusion and exclusion criteria, Oculomotor and Mental scores
were higher in PSP, while MSA patients showed higher scores for
Tremor, Cerebellar, Orthostatic and Urinary symptoms (Figure 2 right).
Table 1. NNIPPS-PPS scores at entry by diagnosis - Internal consistency and inter-rater reliability.
PSP MSA Internal consistency Inter-Rater Reliability
N=362 N=398 N=675 N=116
Dimensional scores (range) Mean ± SD Mean ± SD Cronbach’s a ICC
ADL/Mobility (0–32) 16.466.5
b 15.066.6 0.87 0.93
Axial bradykinesia (0–24) 12.665.5 12.165.8 0.90 0.93
Limb bradykinesia (0–32) 12.866.8 13.766.8 0.93 0.85
Rigidity (0–20) 7.064.3 7.364.7 0.87 0.86
Oculomotor (0–21) 12.864.4
d 2.362.7 0.94 0.87
Cerebellar (0–24) 1.061.8 5.165.1
d 0.89 0.83
Bulbar/Pseudo-bulbar (0–24) 10.664.4
d 9.264.4 0.82 0.89
Mental (0–38) 11.665.9
d 7.565.0 0.78 0.77
Orthostatic (0–12) 0.762.0 2.763.5
d 0.85 0.82
Urinary (0–10) 1.662.0 3.762.9
d 0.68 0.93
Limb dystonia (0–16) 0.661.4 0.661.8 0.76 0.75
Axial dystonia (0–12) 1.162.1
a 0.761.7 0.69 0.73
Pyramidal (0–4) 1.461.3 1.461.3 0.39 0.67
Myoclonus (0–12) 0.260.9 0.561.2
c 0.75 0.54
Tremor (0–28) 1.362.1 2.463.3
d 0.81 0.81
Total score (0–309) 91.6630.4
b 84.3630.9 0.92 0.94
Means 6 standard deviation (SD) of the NNIPPS-PPS dimensional and total scores at entry according to diagnosis: Progressive Supranuclear Palsy (PSP), Multiple System
Atrophy (MSA).
All within groups comparisons (mean versus 0) are statistically significant (p,0.001 by Student’s t test). Comparisons between diagnostic groups (Student’s t test):
ap,0.05,
bp,0.01,
cp,0.001,
dp,0.0001.
Columns: Dimension labels (dimension ranges of scores- from 0=normal, to maximum severity). Internal consistency is expressed as Cronbach’s a coefficient, with
threshold for acceptability set at a=0.70. Agreement coefficients (Intra-Class Coefficients-ICC) from the inter-rater reliability study ranged from 0.54 (moderate) to 0.94
(excellent).
ADL=Activities of Daily Living.
doi:10.1371/journal.pone.0022293.t001
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scores unrelated to inclusion/exclusion criteria (n=9) which
contributed to approximately 70 percent of the total score,
dimensional profiles were identical (Figure 2 Left). Importantly,
within each diagnostic stratum, all mean dimensional sub-scores of
the NNIPPS-PPS, including those related to strata inclusion and
exclusion criteria were significantly different from zero (p,0.001
by Student’s t test), indicating that all clinical dimensions were
present in each disorder, although at varying levels (Table 1).
Predictive validity of the total score at inclusion was confirmed by
its strong relation to survival as shown by the univariate Cox
model analysis (relative risk [95% CI] per point score=1.07
[1.014–1.021] p,0.0001). On splitting the sample by quartiles,
survival curves for the four groups were linearly separated
(Figure 3), such that higher scores were associated with a worse
prognosis. Among the 15 dimensional sub-scores, all except six
(Cerebellar, Mental, Limb dystonia, Myoclonus, Tremor, Pyramidal) were
significantly related to survival (Table 2). Multivariate stepwise
Cox model analysis with candidate covariates including baseline
demographic characteristics (strata, gender, disease duration, age
at inclusion, age at onset), global severity scales (HYS, SEADL,
CGI-ds, CGI dysautonomia) and NNIPPS-PPS total score,
showed the latter as best predictor of survival (Table S3).
Inter-rater reliability
A total of 116 patients (MSA n=74, PSP n=42) were analyzed
with a total of 33 evaluators including general neurologists,
geriatricians, as well as experts in movement disorders. The
characteristics of the 116 patients studied (France (n=70), UK
(n=18) and Germany (n=28)) were representative of the overall
NNIPPS ITT population [8] (Table 3). The reliability of the total
score was excellent (ICC=0.94). For 14 of the 15 dimensional sub-
scores, ICC values were substantial to almost perfect and
moderate for one (Myoclonus) (Table 1). Item wise, inter-rater
agreement was considered as acceptable (kw.0.40, moderate to
almost perfect) for 79 items (95%), including substantial for 38
items (kw.0.6) and moderate for 41 (kw 0.4 to 0.6); four items had
slight to fair reliability (kw,0.4), two in the tremor section and two
myoclonus items. On feedback, discrepancies between investiga-
tors’ scores were accounted for (i) fluctuations in the severity of
clinical symptoms and signs during the day, (ii) differences in
interview technique, (iii) scoring of signs such as dystonia or
myoclonus requiring expertise to be detected, and (iv) interpreta-
tion of items (mainly those of the mental function). Based on this
feedback, standard operating procedures were established and
implemented in the clinical trial.
Responsiveness
There were 642 patients with at least two usable assessments
(PSP n=305, MSA n=337) to assess rates of change. In both
groups, the rate of change of the total score was highly significant
(p,10
24), with PSP patients showing a higher progression rate as
compared to MSA (p,10
24). In the PSP group, rates of change
were highly significant (p,10
24) for all but three dimensions
(Orthostatic, Myoclonia, Tremor) and in the MSA group one only
(Orthostatic) was not significant (Table 4). In both groups the rate of
change in Orthostatic score paradoxically showed non-significant
improvement with time, which upon examination was found
Figure 1. Dimensional scores of the PPS according to disease severity. Dimensional sub scores are expressed as percentage of the
maximum possible score in the dimension (as indicated in Table 1, far left column). Comparisons (Student’s t tests) were made between the two sub-
groups defined by the extreme values of the Clinician Global Impression of disease severity (CGI-ds) in the overall study population. CGI Borderline/
Mild illness (score 1–2) n=93, dotted line; CGI Severe/extremely severe illness (score 5–6) n=142, solid line. ns: not significant at p,0.003 with
Bonferroni correction.
doi:10.1371/journal.pone.0022293.g001
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walk anymore. The same bias was found to significantly affect
Cerebellar scores at follow-up. The total score re-calculated without
these two sub-scores revealed little alteration of the slope of change
(Table 4). While there were clear differences in rates of progression
for dimensional sub-scores between PSP and MSA (Figure 4 Left),
when dimensional slopes of change within disease were expressed
as percent of the total score slope, the profile of contribution of
these to overall disease severity progression was remarkably similar
even for dimensions related to inclusion criteria such as Mental or
Urinary dimensions (Figure 4 Right).
There was no difference in the slope of change of the total score
across the different levels of the CGI-ds (21.8 point per year in the
lowest severity group versus 22.1 in the highest severity group,
p=ns) indicating consistency of the scale across disease stages.
Moreover there was no correlation between the baseline total
score and slope of change (Spearman r=0.04, p=ns).
Consistent with the lack of overall treatment effect on survival
or on other functional scales [8], no difference was found between
treatment groups for mean slopes of change in total NNIPPS-PPS
score (Effect Size=0.03).
When calculated across all visits, the standardized response
mean (SRM) was large for both conditions (1.10 overall) with a
higher response for PSP patients (SRM=1.25) than for MSA
patients (SRM=1.00) thus confirming the more rapid progression
in the former.
Compared to UPDRS, SEADL, UMSARS or PSP-RS, sample
size estimates to detect a significant treatment difference in slope
were substantially lower (30% to 60%) with the NNIPPS-PPS total
score, whatever the group of patients considered (Table 5).
Discussion
The NNIPPS-PPS project is unique in attempting to develop
and validate prospectively a comprehensive rating scale for both
PSP and MSA that can be applied in the early stages of disease
when sensitivity and specificity of current consensus diagnostic
criteria are poor [2] or as yet untested [2], [40]. The validation of
the NNIPPS-PPS scale in a large multicentre clinical trial in PSP
and MSA enabled us to prospectively describe and compare
symptoms severity and progression of a population of well
characterised patients in which diagnostic criteria, prospectively
tested against pathology, were both highly sensitive and specific
[8]. Although the research criteria for inclusion in NNIPPS may
differ from criteria for diagnosis in the clinic (e.g., patients with a
pure cerebellar or pure autonomic presentation of MSA, and
patients with PSP developing supranuclear palsy later in disease
evolution, were formally excluded from the trial), our inclusion
criteria were quite liberal. For example, we accepted a very mild
Figure 2. Dimensional profiles of PSP and MSA at entry. Overall profiles of Parkinson Plus Scale dimensional sub scores at entry for Progressive
Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA). Dimensional sub scores are expressed as percentage of the total score to evaluate
relative contribution of each dimension to overall severity score. Comparisons (Student’s t tests) were made between the two strata. PSP n=362,
dotted line; MSA n=398, solid line. Left: sub scores unrelated to strata inclusion/exclusion criteria- three comparisons reached significance level at
p,0.003: Limb bradykinesia, Rigidity and Myoclonia cumulating to 3.4% overall difference in contribution to total score. Right: sub scores related to
strata inclusion/exclusion criteria- all differences are significant at p,0.003 with 28.2% overall difference in contribution to total score. Contributions
of dimensions related to inclusion criteria amount for 27.6% and 17.3% for PSP and MSA respectively; Contributions of dimensions related to
exclusion criteria amount for 4.9% and 11.8% in PSP and MSA respectively.
doi:10.1371/journal.pone.0022293.g002
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in the UPDRS motor examination) [8]. On the whole, our sample
should be relatively close to the clinical population, presenting a
Table 2. Predictive validity of the NNIPPS-PPS total and
dimensional scores on survival.
NNIPPS-PPS scores RR [95%CI] Khi
2 P-Value
Total Score 1.017 [1.014–1.020] 105.42 ,0.0001
Bulbar/Pseudo-bulbar 1.118 [1.093–1.144] 92.37 ,0.0001
ADL/Mobility 1.084 [1.066–1.102] 91.96 ,0.0001
Axial Bradykinesia 1.088 [1.068–1.109] 76.55 ,0.0001
Urinary 1.149 [1.109–1.190] 59.72 ,0.0001
Limb Bradykinesia 1.046 [1.030–1.062] 34.01 ,0.0001
Rigidity 1.066 [1.042–1.091] 29.78 ,0.0001
Axial Dystonia 1.121 [1.069–1.176] 22.21 ,0.0001
Oculomotor 1.037 [1.020–1.055] 18.61 ,0.0001
Orthostatic 1.069 [1.037–1.103] 17.82 ,0.0001
Myoclonus 1.117 [1.027–1.215] 6.65 0.0099
Mental 1.023 [1.005–1.041] 6.13 0.0133
Pyramidal 1.073 [0.990–1.164] 2.94 0.0866
Cerebellar 1.019 [0.996–1.043] 2.65 0.1037
Limb Dystonia 1.041 [0.977–1.109] 1.55 0.2133
Tremor 1.006 [0.971–1.043] 0.12 0.7325
Univariate Cox model survival analysis. NNIPPS-PPS total and dimensional
scores, Relative Risks per point score (RR) [95% confidence Interval] by
descending Khi
2. Intent to treat study population n=760. Nine out of fifteen
dimensions were significantly predictive of survival (at p,0.003 with Bonferroni
correction).
doi:10.1371/journal.pone.0022293.t002
Figure 3. Predictive validity: 3-year survival according to NNIPPS-PPS total score at entry. Kaplan-Meier plot of the NNIPPS population
broken down by quartiles of the NNIPPS-PPS total score at entry (grouping from lowest to highest severity: Group 1 score [0–65], Group 2 score [66–
86], group 3 score [87–109], Group 4 score [110–182]. Log-rank analysis showed a highly significant difference (p,0.0001) between the four score
groups with an inversely and linearly ordered survival according to score demonstrating an excellent predictive value of the NNIPPS-PPS.
doi:10.1371/journal.pone.0022293.g003
Table 3. Patients Characteristics - Inter-rater reliability study.
PSP MSA TOTAL
N=42 N=74 N=116
GENDER (F) 46% 45% 46%
AGE (years) 69666 4 686 6 68
AGE AT ONSET (years) (36–77) 65675 9 696 1 68
DISEASE DURATION (years ) 3.961.8 5.061.9 4.662.0
1–2 31% 13% 19%
3–5 52% 49% 50%
6–8 14% 35% 27%
.82 % 4 % 4 %
CGI disease severity (1–6) 3.561.0 3.76.09 3.661.0
Mild/Moderately ill 48% 45% 46%
Markedly ill 31% 36% 34%
Severely/Extremely ill 21% 19% 20%
MODIFIED HOEHN & YAHR
(0–5) Stage 2/2.5
24% 13% 17%
Stage 3 33% 29% 31%
Stage 4 12% 35% 26%
Stage 5 31% 24% 26%
SCHWAB & ENGLAND Activities
of Daily living (0–100%)
54627 49624 50625
Clinical characteristics of the 116 patients who took part to the inter-rater
reliability study. Patients were recruited from 11 centers within the 3
participating countries to the NNIPPS study. Characteristics of these patients
were close to those of the overall population (n=760) [8].
CGI=Clinical Global Impression; PSP=Progressive Supranuclear Palsy;
MSA=Multiple System Atrophy.
doi:10.1371/journal.pone.0022293.t003
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PSP Slope test MSA Slope test Strata
Dimensional scores (max) N=305 P-value N=337 P-value P-value
ADL/Mobility (32) 4.664.4 0.00001 3.164.0 0.00001 0.0001
Axial bradykinesia (24) 4.064.2 0.00001 3.063.4 0.00001 0.002
Limb bradykinesia(32) 4.265.9 0.00001 3.164.8 0.00001 0.007
Rigidity (20) 2.164.3 0.00001 1.463.2 0.00001 0.03
Oculomotor (21) 2.262.7 0.00001 1.062.8 0.00001 0.00001
Cerebellar (24) 0.863.1 0.0001 0.963.0 0.00001 0.92
Bulbar/Pseudo-bulbar (24) 3.263.1 0.00001 2.262.6 0.00001 0.00001
Mental (38) 2.164.5 0.00001 1.463.4 0.00001 0.05
Orthostatic (12) 20.162.0 0.25 20.2262.8 0.15 0.66
Urinary (10) 1.062.1 0.00001 0.862.1 0.00001 0.08
Limb dystonia (16) 0.862.0 0.00001 0.361.7 0.005 0.0006
Axial dystonia (12) 0.761.9 0.00001 0.261.2 0.0008 0.0001
Pyramidal (4) 0.261.1 0.00001 0.261.0 0.001 0.61
Myoclonia (12) 0.0261.1 0.52 0.261.5 0.02 0.14
Tremor (28) 0.162.7 0.94 0.963.5 0.00001 0.001
Total score (309) 25.8620.8 0.00001 18.5618.8 0.00001 0.00001
Total score – 2* (273) 25.2620.1 0.00001 17.8617.8 0.00001 0.00001
PSP and MSA columns: NNIPPS-PPS dimensional and total scores slopes of change (mean 6 SD points per year) by strata; N: number of patients with at least two
usable assessments over the three year follow-up. Maximum (most severe) theoretical scores are indicated in the far left column (brackets).
Strata p value column: p value from ANOVA comparing slope of change between strata.
Slope test columns: p value from within-group t test comparing slopes of change within strata (PSP, MSA) to 0 (no change).
*Total score-2: Cerebellar and Orthostatic scores at follow-up visits were found to be highly biased by interference with walking ability (some items becoming
impossible to rate when the patient was unable to stand), and/or motor disability (eg, rigidity), their respective scorings were removed from this Total score calculation
with minor alteration in the overall PPS slope of change in both groups.
doi:10.1371/journal.pone.0022293.t004
Figure 4. Profiles of PSP and MSA rates of change in dimensional sub scores. Left figure: Slopes of change in dimensional sub scores
(excluding Cerebellar and Orthostatic sub scores) were expressed as percentage of the maximum possible score in the dimension. Progressive
Supranuclear Palsy (PSP), n=362, dotted line; Multiple System Atrophy (MSA), n=398, solid line. PSP patients showed higher rates of progression in
all but two sub scores (Myoclonia and Tremor) compared to MSA patients. Right figure: For each strata, slopes of change in dimensional sub scores
were expressed as percentage of the total score slope of change (excluding Cerebellar and Orthostatic sub scores) to evaluate relative contribution of
each dimension to overall severity progression rate. PSP n=362, dotted line; MSA n=398, solid line. PSP and MSA showed similar profiles for severity
progression with a 15.3% cumulative difference in contribution of dimensions to overall slope, including dimensions related to inclusion/exclusion
criteria (Oculomotor, Mental, Urinary, and Tremor). In both diseases, the Akineto-Rigid and Bulbar syndromes were those contributing most to overall
severity progression (71.6% and 72.2% for PSP and MSA respectively).
doi:10.1371/journal.pone.0022293.g004
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robust generalisation of the results.
The 15 dimensional sub-scores identified through factor analysis
confirmed the hypothesised clinical dimensions, accurately
reflecting the complex clinical profile of these two conditions.
Overall, the dimensional scores at entry demonstrated a
remarkably similar clinical profile in PSP and MSA, with complete
overlap in nine dimensions (Figure 2 Left), together contributing to
about 70% of the total severity score at entry in each disease.
These findings are well supported by the psychometric quality of
the scale to measure disease severity, in terms of reliability,
construct validity, predictivity and sensitivity to change.
Although the data were acquired in the setting of a’ field-type’
study involving numerous clinicians, inter-rater reliability of the
NNIPPS-PPS was high, both at the item level and sub-scores with
95% and 87% with acceptable to high agreement, respectively.
Likewise, total score and all dimensions except the Pyramidal one
showed acceptable to high internal consistency.
For assessment of convergent validity, we chose several generic
evaluations to investigate different approaches of severity assess-
ment. The scale demonstrated a good convergence with other
clinical measures for the overall score and for dimensions where
reference measures could be obtained. Predictive validity of the
scale was clearly demonstrated through survival analysis with total
score and most dimensional scores highly predictive of survival.
Analysis of the repeated measures over the 3 year follow-up
showed that the scale appropriately reflects disease progression
(Table 4), except for Myoclonia which had a very low frequency and
low severity in both conditions, and the Cerebellar and Orthostatic
dimensions which could not be reliably assessed at follow-up once
patients were unable to stand, or were treated for orthostatic
symptoms. On the whole, the slopes of progression of sub scores
also demonstrated a remarkably similar profile in MSA and PSP
(Figure 4 Right). Nevertheless, as previously reported in [8], PSP
patients had more severe symptoms and signs at entry, and had a
faster rate of progression on follow-up compared to MSA in terms
of both functional disability and survival. This difference was
clearly detected with the NNIPPS-PPS scale, demonstrating the
good psychometric quality of the scale (Figure 4 Left). To confirm
the usefulness of the total score as an outcome measure for clinical
interventions, we calculated the standardized response mean
(SRM) which reflects the ability of the scale to detect change. The
NNIPPS-PPS total score was able to detect a smaller effect for
disease progression than we originally hypothesized [8]. Com-
pared to UPDRS, SEADL, PSP-RS or UMSAR scales, the
NNIPPS-PPS scale requires fewer patients to detect a given
treatment effect. However, the absence of a treatment effect with
riluzole precluded the assessment of responsiveness to treatment
[8].
A major concern for the application of any scale is the relation
between rate of progression and disease severity (i.e., linearity).
Non-linearity contributes to bias as the slope varies with disease
severity. We found no correlation between total score slope and
the total score at inclusion, or between slope and CGI-ds, as the
annual decrease remained constant across the different severity
levels, from mild to very severe. This is at variance with the
SEADL for which the annual rate of progression decreased with
greater disease severity (data not shown), or with the UMSARS
[39]. This may be explained by a ceiling effect affecting these
measurements, which was not present with the NNIPPS-PPS.
Several dimensions, Dystonia (axial or Limb), Myoclonia, Cerebellar,
Orthostatic and Pyramidal provided limited information. Although
not frequent and not contributing much to overall disease severity
in our analysis, Dystonia and Myoclonia dimensions showed
acceptable psychometric properties and should be kept as they
may be disabling, of prognostic value when present and
diagnostically useful. Cerebellar and Orthostatic dimensions showed
acceptable construct validity and reliability but their assessments
were biased at follow-up, suggesting the need for revised standard
operating procedures. The Pyramidal dimension proved difficult to
quantify, had low internal consistency and reliability, hence its
contribution to overall disease severity and progression is
questionable. However, nearly 50% of patients in both conditions
presented with pyramidal signs at inclusion [8]. To assess its real
contribution to disease severity and progression the construct of
the Pyramidal dimension should be reconsidered. Lastly, the
Table 5. Sample size estimates (per group) using change in slope of clinical scales.
Patients Parameters NNIPPS- PPS SEADL UPDRS 3 PSP-RS UMSARS
All Mean slope 6 SD 21.3619.3 13.9615.3 9.4610.8 --
Change in slope 30% 144 212 229 --
40% 80 118 129 --
50% 51 76 82 - -
PSP Mean slope 6 SD 25.2620.1 15.7615.9 10.5611.5 8.7610.9 -
Change in slope 30% 112 179 209 274 -
40% 63 102 118 155 -
50% 40 65 76 100 -
MSA Mean slope 6 SD 17.8617.8 12.1614.6 8.4610.0 - 7.168.5
Change in slope 30% 174 253 250 - 251
40% 97 142 140 - 141
50% 62 92 90 - 91
Figures in cells are number of patients to be included per group, at a (2-tailed)=0.05 and 12b=0.80, for different levels (30, 40, 50%) of expected change difference
between groups on annual rate of change. Estimates for PSP, MSA or both groups combined, are based on effect sizes of NNIPPS-PPS, SEADL and UPDRS motor score
(UPDRS-3) from the NNIPPS study, UMSARS [39] and PSP-RS [5]. Mean slopes 6 SD as annual rate of change (points per year) are reported for each scale within each
population.
Abbreviations: PPS=Parkinson Plus scale; SEADL=Schwab & England Activities of Daily Living scale; UPDRS-3=Unified Parkinson Disease Rating Scale (Motor
examination score); PSP-RS=Progressive Supranuclear Palsy Rating Scale; UMSARS=Unified Multiple System Atrophy Rating Scale.
doi:10.1371/journal.pone.0022293.t005
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to complete evaluation of dysautonomia. As it is likely that PSP
could be combined with other tauopathies such as corticobasal
degeneration syndrome (CBD), further work on the scale may
consider adapting the scale for CBD, including elements such as
apraxia. These issues are now being addressed in a new ongoing
study.
The development of a scale should allow an ‘unbiased’
assessment of the full range of functional deficits in the disorders
in question. This is particularly important in complex multisystem
disorders such as PSP and MSA. We chose to design a
comprehensive, more extended scale, rather than to limit the
dimensions to the most characteristic features of PSP and MSA. In
that respect, we have confirmed that the Bulbar syndrome is an
independent dimension with important contributions to disease
severity, progression and prognosis in both conditions. While
cerebellar dysfunction is characteristic of MSA, it also occurs in
PSP, as Steele et al. [41] pointed in their original description of
PSP. Likewise, cognitive abnormalities have often been regarded
as unimportant in MSA [18], but we have shown that these are
relatively common in MSA. In a previous paper [42], we showed
that cognitive impairment substantially increased the false
diagnosis rate in the MSA group. However, the overall rate of
false diagnosis was low (12%) [8] and the cognitive impairment
predicted only a third of these. Thus, these few misdiagnosed cases
cannot account for the decline in mental functioning in patients
diagnosed with MSA. Furthermore, 18.2% of the neuropatholog-
ically confirmed MSA cases were found to be cognitively impaired
a frequency similar to the trial population (i.e., 20%). Although
generally less severe than in PSP, the profile of cognitive
dysfunction in MSA was similar on the Dementia Rating Scale
[42]. Our results confirm that all a priori defined dimensions are
present in both disorders, differing only in terms of degree of
severity or rate of progression.
Overall, the NNIPPS study has provided new insights on the
natural history of PSP and MSA. Our assumptions at the
planning stage were that overall diagnostic accuracy would be
low, particularly early in the disease course and that some overlap
might therefore be present in the assessments of disease severity.
Our results have shown that the NNIPPS diagnostic criteria had
good sensitivity and specificity even at the early stage [8], while
the dimensional profile of disease severity and progression as
analyzed here showed wider overlap than expected. These
findings are not contradictory as the NNIPPS diagnostic criteria
though specific to each condition represented only a partial
aspect of the overall disease severity assessed with the NNIPS-
PPS. On the other hand, our consistent findings of similar
patterns of cognitive disability in MSA and PSP [42] and their
high contribution to overall disease severity and progression,
argue strongly that the current consensus criteria for MSA [40]
should be revised [43], [44].
In conclusion, we have developed a clinical scale combining
features of MSA and PSP, which in the early stages share
common features, making accurate diagnosis difficult. The study
has provided evidence, prospectively collected in a large multi-
centre cohort that there is consistent overlap between these
disorders, differing in degree of severity and progression rates.
Our results show that the NNIPPS-PPS has the psychometric
qualities required to measure disease severity and progression in
both diseases, is efficient for powering trials, and is strongly
predictive of survival. These features make it suitable for
capturing the effect of disease-modifying therapy in clinical trials
for MSA, PSP or aty pical parkinsonian (‘parkinson plus’)
syndromes generically.
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